Read More

Cytokinetics’ Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.

AZN

Read More

Prairie Operating Announces Acquisition Of The Assets Of Nickel Road Operating LLC For A Total Consideration Of $94.5M, Consisting Of $83M In Cash And $11.5M In Deferred Cash Payments; Effective Date Of The Transaction Is February 1, 2024

Prairie Operating Co. (NASDAQ:PROP, the "Company" or "Prairie")))) today announced it has entered into a definitive agreement to acquire the assets of Nickel Road Operating LLC ("NRO") for a total consideration of $94.5

PROP